Working… Menu

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03558503
Recruitment Status : Completed
First Posted : June 15, 2018
Last Update Posted : December 11, 2020
Information provided by (Responsible Party):
UroGen Pharma Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 3, 2020
Actual Study Completion Date : October 21, 2020
Certification/Extension First Submitted : December 9, 2020